Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neumora Therapeutics

Explore full profile

Pioneering a new era of precision medicines for brain diseases

Waltham, United StatesFounded 2020Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2026
Headcount 100–500 Current team size
Total funding $500M–1B Disclosed equity funding

About Neumora Therapeutics

Neumora Therapeutics is pioneering the development of precision medicines for brain diseases, addressing the unmet needs in neuropsychiatric and neurodegenerative disorders. The company operates in the biopharmaceutical sector, focusing on Central Nervous System (CNS) diseases. Neumora's business model revolves around leveraging its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to develop targeted treatments. This approach aims to revolutionize the treatment landscape by focusing on novel mechanisms of action, rather than traditional drug classes. Neumora serves patients suffering from brain diseases, a market that affects over 1.5 billion people globally. The company generates revenue through the development and commercialization of its innovative drug pipeline, which is designed to offer more effective and targeted treatment options.

Source: Dealroom company data

At a glance

Founded
2020
Headquarters
Waltham, United States
Listing
IPO 2023
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A16 investors entered at this stage

Series B and later4 investors entered at this stage

  • Exor
  • Newpath Partners
  • Abu Dhabi Growth Fund
  • Scripps Translational Science Institute

Talent

Book a demo to see the people
Employees mapped 106 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 16 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.8%
🇧🇷 Brazil1.3%
2 countries shown
Web traffic by country
9K monthly visits
across markets
🇺🇸 United States76.7%
🇨🇦 Canada14.4%
🇮🇳 India7.8%
🇫🇷 France1.1%
Top 4 markets shown

Patents

Estimated portfolio value
$38M

30 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neumora Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neumora Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles